Clinical Significance of von Willebrand Factor-Cleaving Protease (ADAMTS13) Deficiency in Patients with Sepsis-Induced Disseminated Intravascular Coagulation
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background : Deficiency of von Willebrand factor-cleaving protease, a disintegrin-like and metalloprotease with thrombospondin type 1 motif 13 (ADAMTS13), is thought to be responsible for platelet aggregation and microthrombi formation, which in turn cause typical thrombotic microangiopathies. This deficiency is found in patients with thrombocytopenia-associated multiple organ failure such as thrombocytopenic purpura and disseminated intravascular coagulation (DIC). We evaluated the clinical significance of ADAMTS13 deficiency in patients with sepsis-induced DIC. Materials and Methods : Nineteen patients with sepsis-induced DIC were enrolled. ADAMTS13 antigen levels were determined by Enzyme-Linked Immunosorbent Assay (ELISA) and activity levels were measured by fluorescence resonance energy transfer assay. Patients were categorized into two groups according to ADAMTS13 antigen level: less than 350 ng/mL or above. Clinical characteristics and survival were compared between the two groups. Results : ADAMTS13 antigen level was less than 350 ng/mL in 7 patients and was above 350 ng/mL in 12 patients. There were no significant differences between the groups for age, sex, severity of illness, and other clinical characteristics. In patients with ADAMTS13 antigen level less than 350 ng/mL, in-hospital mortality was much higher (100% versus 25%, P=0.003) and 7-day survival was much shorter (P=0.023). Conclusion : Deficiency of ADAMTS13 could be thought to be associated with unfavorable outcome in patients with sepsis-induced DIC.
Abstract
Background : Deficiency of von Willebrand factor-cleaving protease, a disintegrin-like and metalloprotease with thrombospondin type 1 motif 13 (ADAMTS13), is thought to be responsible for platelet aggregation and microthrombi formation, which in turn cause typical thrombotic microangiopathies. This deficiency is found in patients with thrombocytopenia-associated multiple organ failure such as thrombocytopenic purpura and disseminated intravascular coagulation (DIC). We evaluated the clinical significance of ADAMTS13 deficiency in patients with sepsis-induced DIC. Materials and Methods : Nineteen patients with sepsis-induced DIC were enrolled. ADAMTS13 antigen levels were determined by Enzyme-Linked Immunosorbent Assay (ELISA) and activity levels were measured by fluorescence resonance energy transfer assay. Patients were categorized into two groups according to ADAMTS13 antigen level: less than 350 ng/mL or above. Clinical characteristics and survival were compared between the two groups. Results : ADAMTS13 antigen level was less than 350 ng/mL in 7 patients and was above 350 ng/mL in 12 patients. There were no significant differences between the groups for age, sex, severity of illness, and other clinical characteristics. In patients with ADAMTS13 antigen level less than 350 ng/mL, in-hospital mortality was much higher (100% versus 25%, P=0.003) and 7-day survival was much shorter (P=0.023). Conclusion : Deficiency of ADAMTS13 could be thought to be associated with unfavorable outcome in patients with sepsis-induced DIC.
참고문헌 (17)
- Moake JL, "Thrombotic microangiopathies", N Engl J Med, 347, pp.589~600 (2002)
- Furlan M, "Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura", Blood, 91, pp.2839~2846 (1998)
- Mannucci PM, "Changes in health and disease of the metalloprotease that cleaves von Willebrand factor", Blood, 98, pp.2730~2735 (2001)
- Loof AH, "Low activity of von Willebrand factor-cleaving protease is not restricted to patients suffering from thrombotic thrombocytopenic purpura", Br J Haematol, 112, pp.1087~1088 (2001)
- Moore JC, "Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders", Blood, 98, pp.1842~1846 (2001)
- Nguyen TC, "Bench-to-bedside review: thrombocytopenia-associated multiple organ failure-a newly appreciated syndrome in the critically ill", Crit Care, 10, pp.235~ (2006)
- Green J, "The tissue factor and plasminogen activator inhibitor type-1 response in pediatric sepsis-induced multiple organ failure", Thromb Haemos, 87, pp.218~223 (2002)
- Ono T, "Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure", Blood, 107, pp.528~534 (2006)
- American College of Chest Physicians, "Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis", Crit Care Med, 20, pp.864~874 (1992)
- Gando S, "Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis", Crit Care Med, 30, pp.1729~1734 (2002)
- Knaus WA, "APACHE II: a severity of disease classification system", Crit Care Med, 13, pp.818~829 (1985)
- Kokame K, "FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay", Br J Haematol, 129, pp.93~100 (2005)
- Bianchi V, "Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura", Blood, 100, pp.710~713 (2002)
- Mannucci PM, "Von Willebrand factor cleaving protease (ADAMTS- 13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis)", Haematologica, 88, pp.914~918 (2003)
- Nguyen TC, "Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis", Haematologica, 92, pp.121~124 (2007)
- Furlan M, "Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis", Blood, 87, pp.4223~4234 (1996)
- Nguyen TC, "Plasma therapies in thrombotic syndromes", Int J Artif Organs, 28, pp.459~465 (2005)